2024
Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial
Ogbuagu O, Molina J, Chetchotisakd P, Ramgopal M, Sanchez W, Brunetta J, Castelli F, Crofoot G, Hung C, Ronot-Bregigeon S, Margot N, Wang H, Dvory-Sobol H, Rhee M, Segal-Maurer S. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial. Clinical Infectious Diseases 2024, ciae423. PMID: 39206943, DOI: 10.1093/cid/ciae423.Peer-Reviewed Original ResearchMultidrug-resistant HIV-1Optimized background regimenHIV-1 RNA <CD4 cell countHIV-1Food & Drug AdministrationAdverse eventsTreatment of HIV-1 infectionRates of virologic suppressionCD4 cell count <Treatment-related adverse eventsMulti-drug resistant HIV-1Cell countTreatment-experienced peopleCell count <HIV-1 infectionHIV-1 RNAPhase 2/3 trialsImportant treatment optionInjection site reactionsResistant HIV-1US Food & Drug AdministrationBackground regimenVirologic suppressionStudy drug
2018
Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical setting
Jacobson K, Ogbuagu O. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical setting. Medicine 2018, 97: e13016. PMID: 30412140, PMCID: PMC6221636, DOI: 10.1097/md.0000000000013016.Peer-Reviewed Original ResearchConceptsVirologic suppressionInhibitor-based regimensAntiretroviral therapyMedian timeIntegrase strand transfer inhibitor (INSTI) classHuman immunodeficiency virus-infected patientsIntegrase inhibitor-based regimensMedian baseline CD4 countHuman immunodeficiency virus (HIV) patientsRetrospective single-center studyClinical settingProtease inhibitorsReal-world clinical settingART regimen typeVirologic suppression ratesBaseline CD4 countSingle-center studyVirus-infected patientsCells/μLCopies/mLStudy inclusion criteriaNon-nucleoside reverseRoutine clinical settingLower median timeART initiation
2017
Comparison of Time to Viral Suppression Among Treatment-Naïve HIV-Infected Adults Initiating Combination Antiretroviral Therapy by Antiretroviral Regimen Class
Jacobson K, Ogbuagu O. Comparison of Time to Viral Suppression Among Treatment-Naïve HIV-Infected Adults Initiating Combination Antiretroviral Therapy by Antiretroviral Regimen Class. Open Forum Infectious Diseases 2017, 4: s432-s432. PMCID: PMC5630773, DOI: 10.1093/ofid/ofx163.1090.Peer-Reviewed Original ResearchViral suppressionAntiretroviral therapyART initiationMedian timeART regimensHIV patientsRetrospective single-center chart reviewTreatment-naïve HIV patientsSingle-center chart reviewProtease inhibitorsART regimen typeTreatment-naïve HIVCombination antiretroviral therapyBaseline viral loadTreatment of HIVStudy inclusion criteriaNon-nucleoside reverseRoutine clinical settingLower median timeART regimenINSTI regimensNonstandard regimensRegimen typeVirologic suppressionVirologic failure
2016
Steroid-exacerbated HIV-associated cutaneous Kaposi’s sarcoma immune reconstitution inflammatory syndrome: ‘Where a good intention turns bad’
Chabria S, Barakat L, Ogbuagu O. Steroid-exacerbated HIV-associated cutaneous Kaposi’s sarcoma immune reconstitution inflammatory syndrome: ‘Where a good intention turns bad’. International Journal Of STD & AIDS 2016, 27: 1026-1029. PMID: 26769754, DOI: 10.1177/0956462415627735.Peer-Reviewed Case Reports and Technical NotesConceptsImmune reconstitution inflammatory syndromeReconstitution inflammatory syndromeKS-IRISInflammatory syndromeKaposi's sarcomaKS lesionsSkin lesionsKaposi's sarcoma immune reconstitution inflammatory syndromeFull virologic suppressionNeck skin lesionsParadoxical worseningVirologic suppressionAntiretroviral therapyInitial presentationImmunodeficiency syndromeSteroid useClinician awarenessFacial lesionsLesionsSyndromeSarcomaGlucocorticoidsSteroidsCase discussionChemotherapy
2015
CD8 T-Cell Lymphocytosis and Associated Clinical Syndromes in HIV-Infected Patients.
Tiberio PJ, Ogbuagu OE. CD8 T-Cell Lymphocytosis and Associated Clinical Syndromes in HIV-Infected Patients. Aids Reviews 2015, 17: 202-11. PMID: 26679852.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements